The Management Team
We have a world class leadership team guiding us in our quest to develop the best medicines for our best friends.
Be part of the Transformation in veterinary medicine
We love the pets around us – our dogs, cats, and horses we share our lives with. Many of us believe these animals are part of the family, providing us unconditional love and companionship throughout our lives. We have an opportunity for cutting edge treatment when disease and chronic conditions cross our path, but what happens when our animal companions encounter these same issues?
Treatment options for our companion animals shouldn’t be limited
Download the Corporate Presentation to learn more about our strategy, team, and programs.
Read the Recent News from KindredBio.
Looking for More?
See Our Pipeline
KindredBio has an exciting pipeline of high-value products for dogs, cats, and horses in development.
$4.43 
-0.02 (-0.45%)
-0.02 (-0.45%)
|
||||||||||||||||
KindredBio proudly supports
Rabies Free Africa
Kindred Biosciences to Announce Second Quarter 2020 Financial Results
/in Frontpage, Investor, News /by Katja BuhrerCompany to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Wednesday, August 5, 2020. San Francisco, California (July 23, 2020) — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its second quarter 2020 financial results on August 5, […]
Kindred Biosciences Announces Plan to Strengthen its Strategic Position
/in Frontpage, Investor, News /by Katja BuhrerSan Francisco, California (June 8, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced a plan to enhance its strategic position. The company will prioritize its most attractive late stage programs and substantially reduce expenses to best position it for success with the […]
Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart
/in Frontpage, Investor, News /by Katja BuhrerSan Francisco, California (May 20, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics, today announced it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT) for the manufacture of Vaxart’s oral vaccine candidate for COVID-19. “We are proud to be contributing toward the effort to develop a COVID-19 vaccine. […]